Out of the 11 tested drugs, we found that only the drugs of Group 1, Ruxolitinib, Baricitinib, Dinaciclib and Ganetespib, demonstrated significant inhibition of IFNγ-dependent PD-L1 (59.4 ± 0.62, 70.7 ± 1.63, 46.2 ± 1.93 and 41.29 ± 1.68% inhibition, respectively) and CXCL10 expression (97 ± 2.9, 99 ± 0.2, 100 ± 0.25 and 98 ± 0.62% inhibition, respectively) in Panc1 human pancreatic cancer cells (Figure 7) compared to cells treated only with IFNγ. This evidence concerns the gene CXCL10 and familial pancreatic carcinoma.